ALMS Alumis Inc.
$6.51▼ -3.98%
Healthcare
Other
Volume 1.12M
Avg Volume (10D) 1.81M
Key Metrics & Fundamentals
Market Cap
$842.62M
P/E Ratio
–
Div Yield
0.00%
52W Range
4.39 - 31.35
% vs 50 MA
-42.16%
% vs 200 MA
-70.02%
RSI-14
31.5
MACD Histogram
+0.4000
Beta (1Y vs SPY)
1.75
Free Cash Flow
-$81.74M
Gross Rev
$1.66M
Gross Profit
$1.66M
EBITDA
-$64.33M
COGS
–
Operating Exp
$108.69M
Operating Income
-$107.03M
EBIT
-$107.03M
Pretax Income
-$143.98M
Net Income
-$142.22M
EPS (Diluted)
-1.11
Price & Volume History
Loading chart…
Recent News
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
Clinical Trials Arena · Oct 9, 2026 1:11 PM ET
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
GlobeNewswire · Oct 9, 2026 4:00 AM ET
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
GlobeNewswire · Oct 8, 2026 8:00 AM ET
Top Premarket Gainers
MT Newswires · Sep 10, 2026 7:10 AM ET
Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing
MT Newswires · Sep 10, 2026 4:02 AM ET
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
Insider Monkey · Sep 8, 2026 9:30 PM ET
Alumis to Participate in Upcoming September Investor Conferences
GlobeNewswire · Sep 4, 2026 8:00 AM ET
Is Alumis (ALMS) Overvalued After Its 121% One Year Return?
Simply Wall St. · Sep 3, 2026 10:10 AM ET
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy
Simply Wall St. · Sep 3, 2026 8:15 AM ET
Guggenheim Downgrades Alumis to Neutral From Buy
MT Newswires · Sep 3, 2026 7:15 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ALMS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.